BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38310192)

  • 21. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
    Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
    Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
    Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
    Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M; Zhang Y; Wang Z; Qian N; Dai G
    Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
    Forero-Torres A; Varley KE; Abramson VG; Li Y; Vaklavas C; Lin NU; Liu MC; Rugo HS; Nanda R; Storniolo AM; Traina TA; Patil S; Van Poznak CH; Nangia JR; Irvin WJ; Krontiras H; De Los Santos JF; Haluska P; Grizzle W; Myers RM; Wolff AC;
    Clin Cancer Res; 2015 Jun; 21(12):2722-9. PubMed ID: 25779953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
    Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
    Xu B; Cheng H; Li K; Lv Y; Zeng X; Liu T; Yu W; Guo W
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3029-3038. PubMed ID: 34973080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
    Gentzler RD; Mohindra NA; Jalal SI; Reckamp KL; Hall RD; Hanna NH; Chae YK; Koczywas M; Helenowski IB; Patel JD
    Oncologist; 2024 Jan; 29(1):47-56. PubMed ID: 37390616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
    Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
    Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
    Deutschmann C; Bartsch R; Singer CF; Gschwantler-Kaulich D; Seifert M; Leser C; Marhold M; Bago-Horvath Z; Pfeiler G
    BMC Cancer; 2022 Oct; 22(1):1099. PubMed ID: 36289467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
    J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
    Hattori M; Masuda N; Takano T; Tsugawa K; Inoue K; Matsumoto K; Ishikawa T; Itoh M; Yasojima H; Tanabe Y; Yamamoto K; Suzuki M; Pan W; Cortes J; Iwata H
    Cancer Med; 2023 May; 12(9):10280-10293. PubMed ID: 36916728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
    Biganzoli L; Cinieri S; Berardi R; Pedersini R; McCartney A; Minisini AM; Caremoli ER; Spazzapan S; Magnolfi E; Brunello A; Risi E; Palumbo R; Leo S; Colleoni M; Donati S; De Placido S; Orlando L; Pistelli M; Parolin V; Mislang A; Becheri D; Puglisi F; Sanna G; Zafarana E; Boni L; Mottino G
    Breast Cancer Res; 2020 Aug; 22(1):83. PubMed ID: 32758299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Bianco N; Milano M; Pagan E; Oriecuia C; Bagnardi V; Rocco EG; Santomauro GI; Peruzzotti G; Colleoni M; Viale G
    Breast Cancer Res Treat; 2022 Jan; 191(1):137-145. PubMed ID: 34609640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
    Narayan P; Wahby S; Gao JJ; Amiri-Kordestani L; Ibrahim A; Bloomquist E; Tang S; Xu Y; Liu J; Fu W; Song P; King-Kallimanis BL; Hou S; Gong Y; Kalavar S; Ghosh S; Philip R; Goldberg KB; Theoret MR; Blumenthal GM; Kluetz PG; Sridhara R; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 May; 26(10):2284-2289. PubMed ID: 32001481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.
    Ghebeh H; Al-Sayed A; Eiada R; Cabangon L; Ajarim D; Suleman K; Tulbah A; Al-Tweigeri T
    Sci Rep; 2021 Sep; 11(1):19154. PubMed ID: 34580336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.